☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Takeda
Takeda’s Adzynma (apadamtase alfa/cinaxadamtase alfa) Receives MHLW’s Approval for the Treatment of Congenital Thrombotic Thromboc...
March 27, 2024
Insights+: The US FDA New Drug Approvals in February 2024
March 14, 2024
The US FDA Approves Takeda’s Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis (EoE)
February 14, 2024
Takeda Reports the Results for TAK-861 in P-IIb Trials and Expects to Advance into P-III Trial for the Treatment Narcolepsy Type 1
February 9, 2024
Takeda Receives the US FDA’s Approval for GAMMAGARD LIQUID to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 30, 2024
Takeda’s Hyqvia Receives the US FDA Approval as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 18, 2024
Load more...
Back to Home